The preliminary findings were reported here at the Society of Gynecologic Oncology’s Annual Meeting on Women’s Cancer. The phase III, randomized, controlled trial included women with platinum-sensitive recurrent ovarian cancer…
Based on analysis of two large breast cancer databases, reduced activity of an autophagy gene, beclin 1, was related to both a higher incidence of triple-negative breast cancer and a poorer prognosis for breast cancer patients. …
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. …
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in progression-free survival (PFS0 for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment letrozole and palbociclib, compared to letrozole alone. “We’re essentially putting the brakes on cell proliferation and causing these tumor cells to stop growing,” said Dr. Richard Finn, associate professor of medicine at UCLA and lead author of the study…
An investigational drug discovered and being developed by Pfizer Inc., palbociclib targets a key family of proteins (CDK4/6) responsible for cell growth by preventing them from dividing. Results of the multi-year phase 2 study showed a significant increase in PFS for patients with advanced breast cancer that was estrogen receptor positive (ER+), HER2-negative (HER2-), who were given a combination of the standard anti-estrogen treatment, letrozole, and palbociclib compared to letrozole alone. …
And since trastuzumab, and not chemotherapy alone, is the standard of care for the HER2-positive sub-class of breast cancer, there is no need to test for these lymphocytes in HER2-positive patients in order to predict outcome, say researchers from Mayo Clinic in Florida. These findings, presented at the 2014 San Antonio Breast Cancer Symposium, don’t mean that immune function in this class of cancer isn’t important — just that it is likely more complicated than measuring the number of these lymphocytes, says the study’s lead author, Edith A. Perez, M.D., deputy director at large, Mayo Clinic Cancer Center, and director of the Breast Cancer Translational Genomics Program at Mayo Clinic in Florida. …
Radiotherapy uses X-rays to destroy cancer cells but this can often lead to a severe skin reaction involving redness, pain and blistering similar to sunburn. The trial of this cream — mometasone furoate–was so successful that the patients in the research will now be offered this instead of the existing treatment. Breast cancer patients were recruited from hospitals all over the North West for the trial, based at the Rosemere Cancer Centre at the Royal Preston Hospital. Dr Andrew Hindley of Rosemere Cancer Centre: “We believe that this treatment should be considered the standard of care when a radiation therapy schedule is administered to an anatomical site where severe dermatitis would be predicted.” The patients were offered either diprobase cream or mometasone furoate to be administered daily from the start of radiation therapy for 5 weeks and for at least a fortnight afterwards. …
Published today in Nature, the study examined an antibody (MPDL3280A) which blocks a protein (PD-L1) thought to help cancer cells evade immune detection. In a phase one, multi-centre international clinical trial, 68 patients with advanced bladder cancer (who had failed all other standard treatments such as chemotherapy) received MPDL3280A, a cancer immunotherapy medicine being developed by Roche. In addition, patients were all tested for the protein PD-L1 and around 30 were identified as having PD-L1 positive tumours. After six weeks of treatment, 43 per cent of PD-L1-positive patients found their tumour had shrunk…
Published today in Nature, the study examined an antibody (MPDL3280A) which blocks a protein (PD-L1) thought to help cancer cells evade immune detection. In a phase one, multi-centre international clinical trial, 68 patients with advanced bladder cancer (who had failed all other standard treatments such as chemotherapy) received MPDL3280A, a cancer immunotherapy medicine being developed by Roche. In addition, patients were all tested for the protein PD-L1 and around 30 were identified as having PD-L1 positive tumours. After six weeks of treatment, 43 per cent of PD-L1-positive patients found their tumour had shrunk…
“We found significant disparities for treatment of a curable cancer based on race, insurance status, and whether or not treatment was at an academic or community hospital,” said Dr. …